PODCAST (pod-cast) Definition: Stands for Personal, On-Demand, broadCAST. A short audio or video recording produced to inform or respond to
the public. Commonly, produced online, free and with the ability to subscribe.
ALS TDI is committed to creating and maintaining the most direct and open lines of communication with the ALS community. In support of this
effort, the Institute will be publishing a regular podcast on its website as well as via publishing mechanisms on iTunes. These podcasts are
audio based and last between 7-10 minutes in length, each focusing on a limited topic or number of topics. Click below to listen to recent
podcasts or subscribe to the podcast in order to receive automated notifications via RSS or iTunes when a new ALS TDI podcast is published and available.
07/15/2011 - The National ALS Registry
A frank discussion with the CDC staff in charge of the registry's design, execution, and data interpretation. Hosted by Steve Perrin, CEO of ALS TDI, this 90 minute conversation offers more details about the National ALS Registry than previously discussed.
07/15/2011 - Introduction to ALS Research
You will learn during this hour presentation the basics of ALS, the preclinical process of drug development using small molecules, biologics and gene therapies to slow it down as well as the clinical trial stages. Several real world examples from the lab and clinic are discussed in detail.
05/31/2011 - ALS Advocacy: Examples of Effective Campaign
This is an hour interview with Annie Kennedy (SVP of Advocacy at MDA) and Carol Hamilton (Director of Government Relations and Foundations at ALS TDI). The podcast was recorded on May 4th.
05/17/2011 - Biogen Idec Phase III Clinical Trial "Empower"
Doug Kerr, M.D., Ph.D. is a Medical Director in Experimental Neurology at Biogen Idec and the lead on their newly launched Phase III clinical trial in ALS. During this 20 minute interview, Kerr walks us through how Biogen Idec got to this point, how it designed the trial and what patients can expect from the trial in the clinic. The trial began enrolling in April 2011 and has a goal of 804 patients enrolled through 83 locations in North America, Europe and Australia.
04/11/2011 - Research & Development Update from ALS TDI
This 75 minute discussion is with Steve Perrin, Ph.D., John Lincecum, Ph.D. and Fernando G. Vieira, M.D. of ALS TDI. During which, they discuss several of the projects at the Institute, why these projects were chosen, the biology behind then and the innovative ways the team is overcoming obstacles in the lab today. Dr. Perrin also provides a provocative road map to how the field must enter a "new era" of drug development.
03/21/2011 - Familial ALS: Current Efforts in the Lab and the Clinic
This month's webinar featured Dr. Fernando Vieira from ALS TDI and Dr. Michael Benatar from the University of Miami's Miller School of Medicine. Together they walk us through the known genetics of ALS, how that information is being used in the lab today to identify "pathways" as well as to test potential therapeutics, and current clinical investigations relevant to fALS families.
03/07/2011 - What is Electrical Impedance Myography (EIM)? What does it mean to ALS research?
The conversation includes a description about how the team came up with the idea at the convergence of several field of science, tips for young investigators and information about how the technology is already being used in the clinic today as well as some forward looking thoughts on the future of EIM as a biomarker of ALS disease progression. Rob Goldstein of ALS TDI interviewed Dr. Rutkove for this podcast. Seward is a neurologist, neurophysiologist and nonscientist based at Beth Israel Deaconess Medical Center in Boston and affiliated with Harvard Medical School.
02/24/2011 - The ALS Clinical Trial Process
This month, we present a discussion between two of the field's most experienced leaders, the process of bringing drugs from the lab bench to the bedside is thoroughly explored - blown apart - and pieced back together from a patient's point of view. We take Drs. Merit Cudkowicz (NEALS/MGH/Harvard) and Steve Perrin (CEO of ALS TDI) out of their comfort zones and ask the hard questions on the minds of those living with neurodegenerative diseases such as ALS today.
02/22/2011 - 2010 Milestones and 2011 Goals
This year we kicked off our monthly webinar series with a discussion between Dr. Steve Perrin (CEO of ALS TDI) and Rob Goldstein (Dir. of Comm.) on what was accomplished in 2010 at ALS TDI and some forward looking statements on the Institute's goals for 2011. The podcast is about 45 mins long and is a recording of a live webinar.
06/01/2010 - ALS Advocacy in Washington DC
Annie Kennedy, VP of Advocacy for the MDA and Carol Hamilton, Director of Government Affairs and Foundations at ALS TDI, discuss the current climate and activities in Washington DC to increase funding for ALS research.
04/02/2010 - The ALS TDI Nature Genetics Paper: What does it mean?
This podcast features a conversation with Steve Perrin (CEO/CSO), John Lincecum (Director of Research Biology) and Fernando Vieira (Director of In Vivo Validation) regarding their paper published on 3/28/10 in Nature Genetics. The team talks about the immune system, the mouse model results, what the significance of the human blood sampling is, and some of the potential next steps for this potential treatment (antiCD40L or ALS TDI 00846) for ALS may be.
03/05/2010 - Screening Potential Therapeutics in the SOD1 Mouse
Dr. Fernando Vieira, Director of In Vivo Operations ALS TDI, discusses how his team at ALS TDI, with a combined 100 years of experience in pharmacology and research, use this model of neurodegeneration, and other technologies to identify, screen and validate potential therapeutics in the battle against ALS.
02/18/2010 - ALS Ambassadors Ted & Wendy Reich talk about Finding ALS TDI
Shortly after their son Corey was diagnosed with ALS at age 21, the Reiches met former ALS TDI president Sean Scott at an ALS Research 101 event in California. In this podcast, the couple talk about their candid relationship with Sean and their family's decision to fight Lou Gehrig's disease and raising nearly $1 million in less than two years to date.
02/01/2010 - How is ALS TDI funded?
The Institute's VP of Development, Sally Gould, CFRE, talks about the many ways that people, corporations and foundations fund research at ALS TDI. Hrs. Gould discusses grassroots fundraising, major gifts, bequests and other mechanisms that donors use to impact the speed of ALS research.
02/01/2010 - How far are we from an effective therapeutic for ALS?
Dr. Steve Perrin, CEO/CSO of ALS TDI provides a review of the advancements in the field over the past three years, discusses current clinical trials of high-interest to him and provides insight into what those living with ALS today can do today and how their caregivers and families can help.